TA
ONCE

TCG Advisors’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

TCG Advisors’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-215
Closed -$22K – 461
2019
Q2 		$22K Hold
215
– – 0.02% 206
2019
Q1 		$24K Buy
+215
New +$15.8K 0.02% 210

Other funds holding ONCE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AQR Arbitrage
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

TCG Advisors's ONCE Position: Q3 2019 in Review

TCG Advisors sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q3 2019, closing a stake of 215 shares — an estimated $22K sold.

TCG Advisors first reported a position in ONCE in Q1 2019 and held it in 2 quarters. The position peaked at $24K in Q1 2019. 184 funds tracked by Wall St. Rank hold ONCE as of Q3 2019.

  • TCG Advisors reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • TCG Advisors sold 215 Spark Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $22K.
  • TCG Advisors first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2019 and held it in 2 quarters.
  • TCG Advisors's Spark Therapeutics, Inc. Common Stock position peaked at $24K in Q1 2019.
  • 184 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q3 2019.

Based on TCG Advisors's 13F filing for Q3 2019, filed 13 Nov 2019.